As 2026 begins, global healthcare regulatory bodies are fast-tracking the integration of neoantigen-based therapies into standard care frameworks for non-small cell lung cancer. This shift is marked by the recent World Health Organization guidelines that emphasize the transition from generic immunotherapy to patient-specific molecular targeting. Clinical centers from Boston to Bangalore are now...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek